The risk of bleeding with the continuation of warfarin compared with that for the discontinuation or reduction of the dose of warfarin was expressed as a relative risk (RR) with an associated 95% CI. For this analysis, an RR < 1.0 favoured the continuation of the usual warfarin, a RR > 1.0 favoured the discontinuation or alteration of the warfarin dose, whereas an RR of 1.0 indicated equivalence between the 2 groups.